目的观察理气化瘀汤对气滞血瘀型原发性痛经患者疗效的影响。方法采用随机临床对照研究方法,将148例患者分为对照组74例,治疗组74例。对照组予常规隔下逐瘀汤,治疗组予理气化瘀汤,通过比较VAS疼痛评分、COX痛经症状积分及用药安全性来...目的观察理气化瘀汤对气滞血瘀型原发性痛经患者疗效的影响。方法采用随机临床对照研究方法,将148例患者分为对照组74例,治疗组74例。对照组予常规隔下逐瘀汤,治疗组予理气化瘀汤,通过比较VAS疼痛评分、COX痛经症状积分及用药安全性来评价理气化瘀汤的临床疗效。结果经过3个月经周期的治疗,治疗组(理气化瘀汤)能明显降低患者VAS疼痛评分(3.83±1.52 vs 5.37±1.73),COX痛经症状积分(0.87±0.39 vs1.32±0.47;6.43±1.56 vs 8.87±1.73),与对照组比较差异具有统计学意义(P<0.05);同时治疗组对肝功能、肾功能无明显不良影响(P>0.05)。结论理气化瘀汤能有效安全缓解气滞血瘀型原发性痛经患者临床症状,改善患者生活质量。展开更多
OBJECTIVE:To identify Cald1 as a novel regulator of Linggui Zhugan decoction(苓桂术甘汤)for improving insulin resistance in vivo and in vitro.METHODS:Sprague-Dawley rats were randomly assigned to 3 groups that were re...OBJECTIVE:To identify Cald1 as a novel regulator of Linggui Zhugan decoction(苓桂术甘汤)for improving insulin resistance in vivo and in vitro.METHODS:Sprague-Dawley rats were randomly assigned to 3 groups that were received a normal rat chow diet,high-fat diet(HFD),and an HFD plus LGZGD,respectively.The homeostatic model assessment(HOMA)-insulin resistance(IR)index was used to determine IR.Gene microarray methodology was used to identify differentially expressed genes(DEGs)in the three groups of rats.The DEGs associated with IR were confirmed by quantitative real-time polymerase chain reaction.Additionally,Mouse 3 T3-L1 pre-adipocytes were differentiated into mature 3 T3-L1 adipocytes,which were then treated with tumor necrosis factor(TNF)-αto induce cellular IR.Lipid accumulations were identified by Oil Red O staining.Glucose uptake was assessed using the3 H-2-DG test.RESULTS:In this study,we found Cald1 was further screened to validate its biological function in3 T3-L1 adipocytes induced to develop IR.In vitro experiments showed that insulin-stimulated 3 H-2-DG uptake by IR 3 T3-L1 adipocytes was increased after LGZGD intervention,which was associated with a down-regulation of Cald1 expression.CONCLUSION:LGZGD ameliorates HFD-induced IR in rats and TNF-αinduced IR in adipocytes by down-regulating Cald1 expression.展开更多
文摘目的观察理气化瘀汤对气滞血瘀型原发性痛经患者疗效的影响。方法采用随机临床对照研究方法,将148例患者分为对照组74例,治疗组74例。对照组予常规隔下逐瘀汤,治疗组予理气化瘀汤,通过比较VAS疼痛评分、COX痛经症状积分及用药安全性来评价理气化瘀汤的临床疗效。结果经过3个月经周期的治疗,治疗组(理气化瘀汤)能明显降低患者VAS疼痛评分(3.83±1.52 vs 5.37±1.73),COX痛经症状积分(0.87±0.39 vs1.32±0.47;6.43±1.56 vs 8.87±1.73),与对照组比较差异具有统计学意义(P<0.05);同时治疗组对肝功能、肾功能无明显不良影响(P>0.05)。结论理气化瘀汤能有效安全缓解气滞血瘀型原发性痛经患者临床症状,改善患者生活质量。
基金Supported by the 2016 Shenzhen Science and Technology Commission project fund(Mechanisms of Traditional Chinese Medicine Fasting treatment on insulin resistance caused by spleen deficiency and phlegm dampness based on proteomics,No.JCYJ20160427185421516)。
文摘OBJECTIVE:To identify Cald1 as a novel regulator of Linggui Zhugan decoction(苓桂术甘汤)for improving insulin resistance in vivo and in vitro.METHODS:Sprague-Dawley rats were randomly assigned to 3 groups that were received a normal rat chow diet,high-fat diet(HFD),and an HFD plus LGZGD,respectively.The homeostatic model assessment(HOMA)-insulin resistance(IR)index was used to determine IR.Gene microarray methodology was used to identify differentially expressed genes(DEGs)in the three groups of rats.The DEGs associated with IR were confirmed by quantitative real-time polymerase chain reaction.Additionally,Mouse 3 T3-L1 pre-adipocytes were differentiated into mature 3 T3-L1 adipocytes,which were then treated with tumor necrosis factor(TNF)-αto induce cellular IR.Lipid accumulations were identified by Oil Red O staining.Glucose uptake was assessed using the3 H-2-DG test.RESULTS:In this study,we found Cald1 was further screened to validate its biological function in3 T3-L1 adipocytes induced to develop IR.In vitro experiments showed that insulin-stimulated 3 H-2-DG uptake by IR 3 T3-L1 adipocytes was increased after LGZGD intervention,which was associated with a down-regulation of Cald1 expression.CONCLUSION:LGZGD ameliorates HFD-induced IR in rats and TNF-αinduced IR in adipocytes by down-regulating Cald1 expression.
